The U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee (PCAC) is holding a two-day public meeting on July 23–24, 2026 at the FDA White Oak Campus in Silver Spring, Maryland. The committee is reviewing a group of well-known research peptides that were nominated for the 503A Bulk Drug Substances List — the list of ingredients that compounding pharmacies are permitted to use when preparing medications for individual patients.
For anyone following peptide research, this is a notable moment: several of the most-discussed compounds in the field are being evaluated by the FDA at the same time.
According to the FDA's published agenda, the committee is discussing the following substances (each nominated as both free base and acetate), along with the indications for which they were nominated:
Under the U.S. Federal Food, Drug, and Cosmetic Act, section 503A governs which bulk substances licensed pharmacists can use to compound medications. The advisory committee does not make the final ruling — it reviews the science and provides non-binding recommendations to the FDA on whether each substance should be added to (or kept off) the list. The FDA then makes its own decision.
The public comment period for this meeting ran through July 22, 2026, under docket FDA-2025-N-6895. Interest has been high: peptide regulation has become one of the most-searched topics in the wellness and research space in 2026.
Regardless of the committee's recommendations, this review puts a spotlight on the exact compounds that laboratories and researchers work with every day. It also underscores why sourcing matters: for research applications, purity, identity and documentation (such as a certificate of analysis) are what separate a usable reference compound from an unknown one.
Several of the peptides on the FDA's agenda are compounds we supply to the research community, each with a certificate of analysis, strictly for in-vitro laboratory use: